Cleveland BioLabs, Inc.

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CBLI's P/E is negative making this valuation measure meaningless.

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CBLI's P/CF is negative making the measure meaningless.

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CBLI's P/B is negative making this valuation measure meaningless.

Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CBLI is expected to keep pace with its peers on the basis of earnings growth.

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CBLI is trading at a significant discount to its subsector on this measurement.

Lower. A sales growth rate that trails the subsector implies that a company is losing market share.

CBLI significantly trails its peers on the basis of sales growth.